GIFOF
Price
$8.25
Change
+$0.49 (+6.31%)
Updated
Feb 27 closing price
Capitalization
8.78B
GRFS
Price
$8.10
Change
-$0.02 (-0.25%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
5.48B
62 days until earnings call
Interact to see
Advertisement

GIFOF vs GRFS

Header iconGIFOF vs GRFS Comparison
Open Charts GIFOF vs GRFSBanner chart's image
Grifols Sa
Price$8.25
Change+$0.49 (+6.31%)
Volume$4.41K
Capitalization8.78B
Grifols SA
Price$8.10
Change-$0.02 (-0.25%)
Volume$7.41K
Capitalization5.48B
GIFOF vs GRFS Comparison Chart
Loading...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GIFOF vs. GRFS commentary
May 23, 2025

To understand the difference between Grifols SA - Ordinary Shares - Class B (Non-Voting) (GIFOF) vs. Grifols SA - ADR - Level III (GRFS) it is enough to know the definitions of Ordinary Shares - Class B and ADR - Level III

Ordinary Shares - Class B - Generally, Class B shares are issued by a company as a common stock with fewer voting rights and lower dividend priority than Class A shares. Class B may also have lower repayment priority in the event of a bankruptcy.

ADR - Level III - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars. Foreign companies issuing Level-III ADRs are mandated to fulfill all registration and reporting requirements imposed by the SEC. The security is allowed to be listed on a major U.S. stock exchange such as the New York Stock Exchange or the Nasdaq Stock Market. Unlike other types of ADR, Level-III ADRs can raise capital through a public offering within the United State.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (GIFOF: $8.25 vs. GRFS: $8.13)
Brand notoriety: GIFOF and GRFS are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GIFOF: 100% vs. GRFS: 32%
Market capitalization -- GIFOF: $8.78B vs. GRFS: $5.48B
GIFOF [@Pharmaceuticals: Major] is valued at $8.78B. GRFS’s [@Pharmaceuticals: Major] market capitalization is $5.48B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GIFOF’s FA Score shows that 1 FA rating(s) are green whileGRFS’s FA Score has 1 green FA rating(s).

  • GIFOF’s FA Score: 1 green, 4 red.
  • GRFS’s FA Score: 1 green, 4 red.
According to our system of comparison, both GIFOF and GRFS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GRFS’s TA Score shows that 6 TA indicator(s) are bullish.

  • GRFS’s TA Score: 6 bullish, 3 bearish.

Price Growth

GIFOF (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while GRFS (@Pharmaceuticals: Major) price change was +3.50% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.69%. For the same industry, the average monthly price growth was +2.39%, and the average quarterly price growth was -0.07%.

Reported Earning Dates

GRFS is expected to report earnings on Jul 24, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.69% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GIFOF($8.79B) has a higher market cap than GRFS($5.48B). GRFS has higher P/E ratio than GIFOF: GRFS (68.68) vs GIFOF (48.31). GIFOF YTD gains are higher at: 18.195 vs. GRFS (9.207). GIFOF has higher annual earnings (EBITDA): 726M vs. GRFS (640M). GIFOF (557M) and GRFS (544M) have equal amount of cash in the bank . GIFOF (10.9B) and GRFS (11.1B) have identical debt. GRFS (6.54B) and GIFOF (6.46B) have equivalent revenues.
GIFOFGRFSGIFOF / GRFS
Capitalization8.79B5.48B160%
EBITDA726M640M113%
Gain YTD18.1959.207198%
P/E Ratio48.3168.6870%
Revenue6.46B6.54B99%
Total Cash557M544M102%
Total Debt10.9B11.1B98%
FUNDAMENTALS RATINGS
GIFOF vs GRFS: Fundamental Ratings
GIFOF
GRFS
OUTLOOK RATING
1..100
5012
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
5
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8686
PRICE GROWTH RATING
1..100
4946
P/E GROWTH RATING
1..100
9696
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRFS's Valuation (5) in the Pharmaceuticals Major industry is in the same range as GIFOF (6) in the null industry. This means that GRFS’s stock grew similarly to GIFOF’s over the last 12 months.

GRFS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as GIFOF (100) in the null industry. This means that GRFS’s stock grew similarly to GIFOF’s over the last 12 months.

GRFS's SMR Rating (86) in the Pharmaceuticals Major industry is in the same range as GIFOF (86) in the null industry. This means that GRFS’s stock grew similarly to GIFOF’s over the last 12 months.

GRFS's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as GIFOF (49) in the null industry. This means that GRFS’s stock grew similarly to GIFOF’s over the last 12 months.

GRFS's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as GIFOF (96) in the null industry. This means that GRFS’s stock grew similarly to GIFOF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GRFS
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Momentum
ODDS (%)
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bullish Trend 5 days ago
61%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 3 days ago
70%
Declines
ODDS (%)
Bearish Trend 15 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GESOX18.360.01
+0.05%
Lazard Global Equity Select Port Open
PRBLX60.47N/A
N/A
Parnassus Core Equity Investor
IRGUX48.56N/A
N/A
Voya Russell Mid Cap Growth Idx Port S
MSALX24.92N/A
N/A
Morgan Stanley Inst Intl Advtg L
LSSCX21.19N/A
N/A
Loomis Sayles Small Cap Value Instl

GIFOF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GIFOF has been loosely correlated with GRFS. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if GIFOF jumps, then GRFS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GIFOF
1D Price
Change %
GIFOF100%
N/A
GRFS - GIFOF
37%
Loosely correlated
-0.79%
GIFLF - GIFOF
32%
Poorly correlated
N/A
GIKLY - GIFOF
27%
Poorly correlated
-5.26%
AMRN - GIFOF
21%
Poorly correlated
N/A
BAYZF - GIFOF
12%
Poorly correlated
+1.72%
More

GRFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
-0.79%
GIKLY - GRFS
68%
Closely correlated
-5.26%
GIFOF - GRFS
37%
Loosely correlated
N/A
PFE - GRFS
28%
Poorly correlated
N/A
BIIB - GRFS
28%
Poorly correlated
-0.41%
GIFLF - GRFS
23%
Poorly correlated
N/A
More